Skip to main content
. Author manuscript; available in PMC: 2020 Nov 2.
Published in final edited form as: Genet Med. 2018 Feb 8;20(10):1274–1283. doi: 10.1038/gim.2017.262

Figure 2. Metabolomic profile of our study cohort: the peroxisome biogenesis disorders–Zellweger spectrum disorders (PBD-ZSD) metabolome.

Figure 2

(a) Principal components analysis is shown; red squares represent the PBD-ZSD samples, blue circles represent a collection of control samples. The principal components, PC1 and PC2, were generated using all metabolomic data. Percent signs indicate the percent of variation explained by that principal component. (b) Heat map of the PBD-ZSD samples; red shows relative increases, while blue shows reductions. Pathways of the analytes are shown on the left axis (individual analytes in Supplementary Table S4 online). Specific compounds noted to be altered are marked at right. Subjects are labeled according to family designation (see Table 1).